Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1018-1024 , July 2010

Favorable Outcome in Patients with Acute Myelogenous Leukemia with the Nucleophosmin Gene Mutation Autografted after Conditioning with High-Dose Continuous Infusion of Idarubicin and Busulfan

  • Felicetto Ferrara

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • Corresponding Author InformationCorrespondence and reprint requests: Felicetto Ferrara, MD, Via Nicolò Piccinni 6, 80128 Napoli, Italy.
    • ,
  • Tiziana Izzo

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Clelia Criscuolo

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Cira Riccardi

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Giada Muccioli

      Affiliations

    • CEINGE, Federico II University, Naples, Italy
    • ,
  • Assunta Viola

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
    • ,
  • Fabrizio Pane

      Affiliations

    • CEINGE, Federico II University, Naples, Italy
    • ,
  • Salvatore Palmieri

      Affiliations

    • Division of Hematology and Stem cell Transplantation Unit, Cardarelli Hospital, Naples, Italy

Received 5 January 2010 ,Accepted 13 February 2010.

References 

  1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004;5:443–450
  2. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37:649–658
  3. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2008;66:181–193
  4. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–1891
  5. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2233
  6. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115–136
  7. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetcs add to other prognostic factors predicting complete remission and long term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63–73
  8. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266
  9. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloidleukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746
  10. Mrozèk K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood. 2007;109:431–448
  11. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009;27:171–181
  12. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–1918
  13. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B Study. J Clin Oncol. 2009 Dec 21;[Epub ahead of print]
  14. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009;385–395
  15. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008;14:556–567
  16. Ferrara F, Palmieri S, De Simone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol. 2005;128:234–241
  17. Ferrara F, Palmieri S, Pedata M, et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol Oncol. 2009;27:40–45
  18. Ferrara F, Mele G, Palmieri S, et al. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol. 2009;27:198–202
  19. Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L. Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet. 2009;195:164–167
  20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951
  21. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295–1300
  22. Ferrara F, Palmieri S, Pollio F, et al. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant. 2006;12:981–986
  23. Roti G, Rosati R, Bonasso R, et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn. 2006;8:254–259
  24. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica. 2005;90:776–784
  25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  26. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109:874–885
  27. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009;21:573–581
  28. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731–1743
  29. Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113:5250–5253
  30. Cilloni D, Messa F, Rosso V, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia. 2008;22:1234–1240
  31. Palmieri S, Ferrara F, Leoni F, et al. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol. 2007;25:1–5
  32. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. Hematol Oncol. 2009;27:161–170
  33. Hsu FY, Zhao Y, Anderson WF, Johnston PB. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest. 2007;25:240–248
  34. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–1259
  35. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248
  36. Feller N, Schuurhuis GJ, van der Pol MA, et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia. 2003;17:68–75

 Financial disclosure: See Acknowledgments on page 1023.

PII: S1083-8791(10)00082-0

doi: 10.1016/j.bbmt.2010.02.011

Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1018-1024 , July 2010

Article Tools

* Image Usage & Resolution